KR-A- 20060 067 738 (B1)

Wietecha et al: Neurology, vol. 90, no. 15 Supp, April 2018 (2018-04) , (B2)

US-A1- 2008 300 407 (B1)

WO-A1-03/084949 (B1)

WO-A1-2008/114971 (B1)

WO-A1-2011/123654 (B1)

WO-A2-2004/047739 (B1)

WO-A2-2006/081127 (B1)

"Archive History for NCT00883051", , 16 April 2009 (2009-04-16), Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history /NCT00883051?V_1=View (B2)

"Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment", ClinicalTrials.gov, 10 September 2009 (2009-09-10), Retrieved from the Internet: URL:https://web.archive.org/web/2009091022 0814/clinicaltrials.gov/ct2/show/NCT008830 51 (B2)

"PO34 - COL-144, an orally bioavailable selective 5-HT1F receptor agonist fpor acute migraine therapy", Cephalalgia Program Abstracts - 14th Congress of the International Headache SocietyCephalalgia Program Abstracts - 14th Congress of the International Headache Society, vol. 29, no. suppl.1, 10 September 2009 (2009-09-10), - 13 September 2009 (2009-09-13), pages 24-25, (B2)

"Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008", Press Release, 6 September 2008 (2008-09-06), (B2)

Drug Data Report, vol. 31, no. 10, 2009, page 964, (B2)

EMEA: "EMEA General Guidance for Clinical Trials; ICH Topic E 8 - General Considerations for Clinical Trials", EMEA CPMP/ICH/291/95, March 1998 (1998-03), pages 1-14, (B2)

EP-B1- 1 492 786 (B2)

GOLDSTEIN et al.: "Selective seratonin 1F (5-HT"1"F) receptor agonist LY334370 for acute migraine: a randomised controlled trial", The Lancet, vol. 358, 13 October 2001 (2001-10-13), pages 1230-1234, (B2)

Liefaard L. et al.: "PO33 - Prediction of therapeutically effective dose of COL-144 based on relationship between plasma concentrations and headache response", Cephalalgia Program Abstracts - 14th Congress of the International Headache Society, vol. 29, no. suppl.1, 10 September 2009 (2009-09-10), - 13 September 2009 (2009-09-13), page 24, (B2)

Nelson D.L.: "PC.12 - COL-144: Preclinical profile of a selective 5-HT1F receptor agonist for migraine", Abstracts of the European Headache and Migraine Trust International Congress 2008, vol. 29, 4 September 2008 (2008-09-04), - 7 September 2008 (2008-09-07), pages 122-123, (B2)

Reuter U. et al.: "PC.11 - COL-144, a selective 5-Ht1F agonist, for the treatment of migraine attacks", Cephalalgia - Abstracts of the European Headache and Migraine Trust International Congress 2008, vol. 29 4 September 2008 (2008-09-04), 7 September 2009 (2009-09-07), pages 122-123, (B2)

U. Reuter et al.: "Abstract PC.11 - COL-144, a selective 5-HT1F agonist, for the treatment of migraine attacks", Cephalalgia (poster abstracts), vol. 29 1 January 2009 (2009-01-01), page 122, (B2)

US-B2- 7 423 050 (B2)

WHO Drug Information, vol. 23, no. 4, 2009, pages 322-323, (B2)

WO-A2-2010/115125 (B2)

RAMADAN N M: "ACUTE TREATMENTS: SOME BLIND ALLEYS", CURRENT MEDICAL RESEARCH AND OPINION, HANTS, GB, vol. 17, no. SUPPL. 01, 1 January 2001 (2001-01-01), pages S71-S80, XP009054418, (B1)